Last Updated on October 17, 2024 by The Health Master
The US Food and Drug Administration (USFDA) has given tentative approval to Lupin’s Abbreviated New Drug Application (ANDA), Drospirenone tablets, 4 mg.
This approval is to market a generic equivalent of Slynd tablets, 4 mg, of Exeltis USA, a statement from Lupin has notified.
Drospirenone tablets had estimated annual sales of $141 million in the US, the statement said.
USFDA approves Ketorolac Tromethamine injection
USFDA gives final approval for Sodium Phenylbutyrate tablets
USFDA gives approval for Glycopyrrolate injection
USFDA gives final approval for Mesalamine extended-release capsules
USFDA gives final approval for Paclitaxel injection
USFDA gives approval to this Blood Cancer therapy
IPC adds 10 new Impurity Reference Substances to IP 2022
USFDA issues warning letter to Lupin API plant
NPPA to consider Retail Price Fixation of this Asthma Drug Combination
USFDA approves Ketorolac Tromethamine injection
300 Drug Formulations to have mandatory Bar Codes
USFDA gives final approval for Sodium Phenylbutyrate tablets
IPC clarifies on uniformity of dosage units & impurities in IP 2022
USFDA gives approval for Glycopyrrolate injection
NPPA panel recommends retail price fixation for Atorvastatin and Bempedoic acid
Latest Notifications regarding Pharmaceuticals
